Management Team
Martin Welschof
Chief Executive Officer
Ph.D. (Dr.rer.nat.) in recombinant antibody technology. Employed since 2018. He did his postdoctoral training at the German Cancer Research Center, Department for Recombinant Antibody Technology and at the University of Heidelberg, Department of Transplantation Immunology both in Heidelberg, Germany. Martin has a broad international experience from executive positions within the biotech industry, including Director of Technology at Axaron Bioscience AG, Heidelberg, Germany, CEO of Affitech (Nasdaq Copenhagen) and CEO of Opsona Therapeutics, Dublin, Ireland. Member of the Board of APIM Therapeutics AS and Nextera AS. Born 1961.
Shareholding: 22,400
Conditional Employee Options: 812,603
Stefan Ericsson
Chief Financial Officer
MBA, Lund University. Employed since 1998. Chief Financial Officer since 2016 and has previously served as Director Business Control. Previous experience from the Swedish Tax Agency and as auditor at PricewaterhouseCoopers. Born 1963.
Shareholding: 8,000
Conditional Employee Options: 231,370
Björn Frendéus
Chief Scientific Officer
Doctor of Immunology. Employed since 2001. Frequent publisher in leading scientific immunology journals, and speaker and chair at international Immuno-oncology conferences. Inventor on more than 150 patents and patent applications. Visiting Professor at University of Southampton. Born 1973.
Shareholding: 23,089 (own and affiliated holdings)
Conditional Employee Options: 443,238
Andres McAllister
Chief Medical Officer
Doctor in Medicine and Surgery from the Universidad del Rosario (Bogotá), and holds a PhD from the Institut Pasteur/Université Paris 7. Employed since 2017. He has performed academic work at the Pasteur Institut and the University of California, San Francisco on cancer immunotherapy. Andres joins BioInvent from a position as Chief Scientific Officer at Debiopharm, and has previously held senior roles at IDM and BioMérieux/ Pierre Fabre. Born 1956.
Shareholding: 3,009
Conditional Employee Options: 515,184
Marie Moores
Chief Operating Officer
Over 25 years’ experience of transforming international organizations, with expertise in regulatory affairs and building businesses focusing on drug development. Former Executive Vice President, International Operations & Early Development at the Norwegian company LINK Medical Research. She previously spent more than 20 years with Theradex Oncology as Director, Clinical and Regulatory Operations for Europe. Employed 2022. Born 1968.
Shareholding: -
Conditional Employee Options: -
Kristoffer Rudenholm Hansson
Senior Vice President, Technical Operations
Master of Science in Chemical engineering. Employed since 2016 and is responsible for process development and production of antibodies for clinical studies. He has more than 15 years’ experience from managing manufacturing of antibodies and other proteins for clinical use. Kristoffer has held a numerous positions within CMC Biologics A/S (now AGC Biologics), DAKO A/S and Symphogen A/S. Born 1974.
Shareholding: 22,303 (whereof 7,177 in endowment insurance)
Conditional Employee Options: 235,506
Sylvie Ryckebusch
Chief Business Officer
Ph.D. in neurobiology from the California Institute of Technology and BSc degrees in physics and mathematics from the University of Maryland, US. Employed since 2022.
Over 20 years of experience in business development, alliance management, and corporate strategy. Sylvie has served in key positions at Serono, Merck KGaA, and Index Ventures as well as McKinsey and Company and the Harvard Business School. Born 1965.
Shareholding: -
Conditional Employee Options: -